Company Filing History:
Years Active: 2019-2022
Title: Roni Engelstein: Innovator in Cancer Therapy
Introduction
Roni Engelstein is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of immunotherapy, particularly in cancer treatment. With a total of 2 patents, Engelstein's work focuses on innovative methods that enhance T cell modulation for improved patient outcomes.
Latest Patents
Engelstein's latest patents include groundbreaking inventions aimed at cancer therapy. The first patent, titled "Methods for cancer therapy using isolated NTB-A ectodomain polypeptides," is directed towards immunotherapy. This invention provides compositions and methods for improved T cell modulation both ex vivo and in vivo, specifically targeting cancer and other pathologies. The use of soluble NTB-A polypeptides or agonists is emphasized for treating cancer patients and preventing cytopenia in susceptible individuals.
The second patent, "Cell compositions and methods for cancer therapy," also focuses on immunotherapy. Similar to the first, it provides compositions and methods for enhanced T cell modulation for cancer treatment. Engelstein's inventions aim to improve the preparation of cell compositions for therapeutic applications.
Career Highlights
Roni Engelstein is associated with Hadasit Medical Research Services and Development Ltd., where he continues to advance his research in cancer therapy. His work is characterized by a commitment to developing innovative solutions that address critical health challenges.
Collaborations
Engelstein collaborates with notable colleagues, including Abraham Rutenberg and Ronny Uzana. These partnerships enhance the research and development of his innovative therapies.
Conclusion
Roni Engelstein's contributions to cancer therapy through his patents reflect his dedication to improving patient care. His innovative approaches in immunotherapy are paving the way for future advancements in the field.